BPTS Key Statistics, Chart & Performance
The current stock price of BPTS is 8.22 USD. In the past month the price decreased by -41.29%. In the past year, price decreased by -94.66%.
BPTS Technical Analysis
BPTS Financial Highlights
Over the last trailing twelve months BPTS reported a non-GAAP Earnings per Share(EPS) of -7.8. The EPS increased by 63.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -134.02% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BPTS Forecast & Estimates
8 analysts have analysed BPTS and the average price target is 0.38 USD. This implies a price decrease of -95.36% is expected in the next year compared to the current price of 8.22.
BPTS Ownership
About BPTS
Company Profile
Biophytis SA operates as a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France and currently employs 26 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
Company Info
BIOPHYTIS SA-ADR
14 avenue de l'Opera
Paris ILE-DE-FRANCE 75252 FR
CEO: Stanislas Veillet
Employees: 26
Phone: 33141836600
BIOPHYTIS SA-ADR / BPTS FAQ
What does BPTS do?
Biophytis SA operates as a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France and currently employs 26 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
Can you provide the latest stock price for BIOPHYTIS SA-ADR?
The current stock price of BPTS is 8.22 USD. The price decreased by -15.28% in the last trading session.
Does BIOPHYTIS SA-ADR pay dividends?
BPTS does not pay a dividend.
What is the ChartMill technical and fundamental rating of BPTS stock?
BPTS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the analyst forecast for BPTS stock?
8 analysts have analysed BPTS and the average price target is 0.38 USD. This implies a price decrease of -95.36% is expected in the next year compared to the current price of 8.22.
Can you provide the market cap for BIOPHYTIS SA-ADR?
BIOPHYTIS SA-ADR (BPTS) has a market capitalization of 94.20M USD. This makes BPTS a Micro Cap stock.
What is the ownership structure of BIOPHYTIS SA-ADR (BPTS)?
You can find the ownership structure of BIOPHYTIS SA-ADR (BPTS) on the Ownership tab.